Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704

Pre-Clinical Pharmacokinetic Characterization, Tissue Distribution, and Excretion Studies of Novel Edaravone Oral Prodrug, TEJ-1704

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a free radical scavenger approved for the treatment of amyotrophic lateral sclerosis, a fatal neuromuscular disease. Edaravone is administered as an intravenous infusion over 60 min for several treatment cycles. To ease the burden of patients and ca...

Full description

Bibliographic Details
Main Authors: Dong Wook Kang, Ju Hee Kim, Kyung Min Kim, Seok-jin Cho, Hee-Woon Jang, Ji Won Chang, Seung Myung Dong, Jee Woong Lim, Jae-Sun Kim, Hea-Young Cho
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Pharmaceutics
Subjects:
pharmacokinetics
tissue distribution
excretion
edaravone oral prodrug
amyotrophic lateral sclerosis
Online Access:https://www.mdpi.com/1999-4923/13/9/1406

Internet

https://www.mdpi.com/1999-4923/13/9/1406

Similar Items